Modiin Pu (MDIN) AI Stock Analysis

• Market Cap: 37.04M
• Dividend Yield: N/A
• Average Volume (3M): 28.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -17.64%
• EPS Growth: -230.96%
• Country: IL
• Employees: 8
• Sector: Energy
• Sector Strength: 52
• Industry: Oil & Gas Exploration & Production
• EPS (TTM): -0.32
• Shares Outstanding: 34,297,638
• 10 Day Avg. Volume: 18,904
• 30 Day Avg. Volume: 28,000
• PEG Ratio: <0.01
• Price to Book (P/B): 0.30
• Price to Sales (P/S): 0.51
• P/FCF Ratio: -4.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: 103.00 ▼(-0.29% Downside)

The overall stock score is primarily influenced by poor financial performance and weak technical indicators. The lack of profitability and negative market sentiment are significant risks. Valuation metrics further reflect challenges, with no earnings call or corporate events to offset these issues.

Modiin Pu Business Overview & Revenue Model

Company Description

Modiin Pu (MDIN) is a cutting-edge biotechnology company focused on developing advanced therapeutic solutions for the treatment of various diseases. Operating primarily in the healthcare sector, MDIN specializes in the research and development of innovative drug delivery systems and biologics aimed at improving patient outcomes. The company's core product offerings include novel pharmaceuticals, targeted therapies, and proprietary delivery mechanisms that enhance the efficacy and safety of existing treatments.

How the Company Makes Money

Modiin Pu generates revenue through multiple streams, primarily by commercializing its proprietary drug candidates and technologies. The company engages in partnerships with pharmaceutical firms for the co-development of therapeutics, which often includes licensing agreements that provide upfront payments and milestone payments tied to the achievement of specific development goals. Additionally, MDIN earns revenue from selling its drug delivery platforms to other biotech companies. The firm may also receive royalties from successful products that utilize its technologies, thereby creating a diverse revenue model that leverages both direct sales and collaborative ventures within the pharmaceutical industry.

Modiin Pu Financial Statement Overview

Summary

Modiin Pu faces significant financial challenges, with declining revenues and profitability, increased leverage, and cash flow constraints. While the equity ratio remains stable, the overall financial health is weakened by operational inefficiencies and financial risks.

Income Statement

The company experienced a significant decline in revenue, with a negative revenue growth rate of -18.26% in the latest year. Gross profit margin decreased from 59.29% to 51.71%, indicating reduced efficiency in cost management. The net profit margin turned negative, reflecting a net loss, and both EBIT and EBITDA margins declined, suggesting operational challenges.

Balance Sheet

The debt-to-equity ratio increased to 1.49, indicating higher leverage and potential financial risk. Return on equity turned negative, highlighting profitability issues. However, the equity ratio remains stable, suggesting a balanced asset structure.

Cash Flow

Free cash flow growth was negative, and the free cash flow to net income ratio was also negative, indicating cash flow challenges. The operating cash flow to net income ratio improved slightly but remains below 1, suggesting insufficient cash flow generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.47M	23.09M	27.03M	19.86M	17.64M	1.73M
Gross Profit	12.15M	11.94M	16.03M	13.86M	12.41M	628.00K
EBITDA	9.26M	9.10M	11.99M	9.54M	8.26M	-1.43M
Net Income	-8.92M	-9.45M	2.12M	-2.79M	6.56M	-6.02M
Balance Sheet
Total Assets	118.60M	107.23M	106.09M	80.44M	43.16M	13.68M
Cash, Cash Equivalents and Short-Term Investments	13.31M	2.16M	3.61M	1.63M	1.96M	1.33M
Total Debt	75.24M	58.73M	51.90M	31.18M	16.00M	0.00
Total Liabilities	81.56M	67.79M	66.15M	46.64M	20.25M	1.19M
Stockholders Equity	37.04M	39.44M	39.93M	33.79M	22.91M	12.48M
Cash Flow
Free Cash Flow	-5.11M	-2.88M	-18.94M	-23.81M	-15.52M	-1.29M
Operating Cash Flow	10.09M	10.34M	11.91M	11.69M	8.25M	-233.00K
Investing Cash Flow	-16.55M	-13.60M	-32.07M	-38.96M	-25.62M	-3.11M
Financing Cash Flow	15.92M	1.64M	21.99M	27.13M	18.12M	3.02M

Modiin Pu Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 103.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:MDIN, the sentiment is Negative. The current price of 103.3 is below the 20-day moving average (MA) of 111.97, below the 50-day MA of 125.13, and below the 200-day MA of 152.00, indicating a bearish trend. The MACD of -6.38 indicates Positive momentum. The RSI at 17.77 is Positive, neither overbought nor oversold. The STOCH value of 10.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:MDIN.

Modiin Pu Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	$15.17B	7.61	4.09%	5.20%	3.87%	-62.32%
MDIN	41 Neutral	37.04M	―	―	―	-17.64%	-230.96%